Efficacy and safety of eribulin in combination with capecitabine in patients with metastatic breast cancer: an open-label, phase II dose-confirmation study

被引：0
|
作者：
Twelves, Chris [1 ,2 ]
Nasim, Muhammad Y. [3 ]
Anthoney, Alan [1 ,2 ]
Savulsky, Claudio I. [4 ]
Yin, Shuxin [4 ]
Evans, T. R. Jeffry [3 ]
机构：
[1] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[2] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[3] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow G12 8QQ, Lanark, Scotland
[4] Eisai & Co Ltd, Glasgow G12 8QQ, Lanark, Scotland
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P3-13-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-13-04
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [22] An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika Paige
    Chu, Christina
    Richardson, Debra L.
    Arend, Rebecca Christian
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Hays, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] 4CAST: A Phase 1b dose exploration and dose expansion, open-label study evaluating the safety and efficacy of INO-464 in combination with Chemotherapy in patients with metASTatic breast cancer
    Dear, Rachel F.
    Batty, Kathleen
    Perez, Beatriz
    Chaffer, Christine
    CANCER RESEARCH, 2023, 83 (05)
  • [24] An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer
    Salzberg, Marc
    Rochlitz, Christoph
    Morant, Rudolf
    Thalmann, George
    Pedrazzini, Augusto
    Roggero, Enrico
    Schoeneberger, Astrid
    Knuth, Alexander
    Borner, Markus
    ONKOLOGIE, 2007, 30 (07): : 355 - 360
  • [25] Efficacy, safety and cost of eribulin in patients with metastatic breast cancer
    Paillard, Marie-Justine
    Curtit, Elsa
    Dobi, Erion
    Mansi, Laura
    Bazan, Fernando
    Villanueva, Cristian
    Chaigneau, Loic
    Montcuquet, Philippe
    Meneveau, Nathalie
    Thiery-Vuillemin, Antoine
    Nerich, Virginie
    Pivot, Xavier
    BULLETIN DU CANCER, 2015, 102 (09) : 737 - 748
  • [26] A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers
    Roviello, Giandomenico
    Milani, Manuela
    Gobbi, Angela
    Cappelletti, Maria Rosa
    Zanotti, Laura
    Senti, Chiara
    Bottini, Alberto
    Strina, Carla
    Sigala, Sandra
    Generali, Daniele
    CLINICAL BREAST CANCER, 2016, 16 (03) : E57 - E59
  • [27] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study
    Peng, Peijian
    Xu, Xiaolu
    Zhong, Jincai
    Ye, Jin-Hui
    Wang, Zhi-Hui
    Wang, Hong
    Lin, Hong
    Du, Caiwen
    Zou, Guorong
    Ouyang, Jie
    Shi, Ying-ying
    Xu, Fei
    Yu, Gengsheng
    Lu, Yongkui
    Wang, Yong-Xia
    Cui, Shi-En
    Li, Lu-Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study
    Tanaka, Maki
    Takamatsu, Yasushi
    Anan, Keisei
    Ohno, Shinji
    Nishimura, Reiki
    Yamamoto, Yutaka
    Masuda, Norikazu
    Mitsuyama, Shoshu
    Tamura, Kazuo
    ANTI-CANCER DRUGS, 2010, 21 (04) : 453 - 458
  • [29] A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses
    Kaufmann, P. A.
    Cortes, J.
    Awada, A.
    Yelle, L.
    Perez, E. A.
    Wanders, J.
    Olivo, M.
    He, Y.
    Ductus, C.
    Bischoff, J.
    Twelves, C.
    ONKOLOGIE, 2013, 36 : 97 - 97
  • [30] Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
    Cortes, Javier
    Hudgens, Stacie
    Twelves, Chris
    Perez, Edith A.
    Awada, Ahmad
    Yelle, Louise
    McCutcheon, Susan
    Kaufman, Peter A.
    Forsythe, Anna
    Velikova, Galina
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 509 - 520
12345